Rising GLP-1 medication costs have become one of the most urgent challenges for self-funded employers. Demand continues to grow, outcomes remain strong, and employees want access—yet many organizations simply can’t justify the high and unpredictable pharmacy spend tied to drugs like Wegovy® and Ozempic®.
That’s why Xevant’s recent announcement of new lower pricing for GLP-1 medications through Ivim at Work is such a big moment for the employer benefits world. It’s more than a pricing update. It signals a shift toward sustainable, clinically guided GLP-1 programs built specifically for corporate populations.
Whether you manage a self-funded plan, support clients as a broker, or run clinical operations inside a PBM, here’s what you should know.
GLP-1 Costs Are Changing—Fast
Across the industry, manufacturers and telehealth networks are beginning to experiment with reduced or introductory pricing for GLP-1 medications. These changes reflect the growing pressure on the system: people want access, but the historical costs—often $900–$1400 per month—aren’t feasible for employers long-term.
Xevant’s new pricing reflects—and in many cases improves upon—these market trends, making GLP-1 therapy accessible at a level employers rarely see.
New Pricing Through Ivim at Work
- $199/month for the first two doses (0.25 mg and 0.5 mg) of Wegovy® and Ozempic® for new patients
- $349/month, depending on medication and dose, for Wegovy® and Ozempic® continuation doses (1.0 mg, 1.7 mg, 2.4 mg)
- U.S.-sourced supply and full clinical oversight included
For many employers, this is the first time GLP-1 coverage has felt financially realistic.
Built for Employers—Not Consumer Telehealth
There are hundreds of GLP-1 and weight-loss options available directly to consumers, but most of them weren’t built to support the needs of employer health plans. They lack transparency, offer inconsistent pricing, and often focus on dispensing rather than outcomes.
Ivim at Work is different.
It’s the only GLP-1 and weight-health program designed exclusively for employers, integrating:
- Care management
- Coaching and clinical oversight
- Real-time progress tracking
- U.S. pharmacy supply
- Predictable, transparent pricing
- Clear ROI measurement
Employers don’t need another telehealth vendor. They need a corporate-ready solution that aligns with benefit strategy, controls cost, and supports long-term behavior change and metabolic health.
VerX Ensures the Lowest-Cost Path Forward
Lower pricing is powerful—but lower pricing paired with intelligent cost optimization is what truly moves the needle.
Xevant’s VerX pharmacy orchestration platform sits behind Ivim at Work and ensures that every prescription follows the lowest-cost, clinically appropriate route. This means employers don’t just benefit from lower acquisition costs—they also benefit from:
- Optimized dose progression
- Avoidance of unnecessary refills
- Reduction in pharmacy waste
- Alerts for anomalies or misuse
- Real-time savings identification
In short:
Ivim at Work lowers the price. VerX keeps it optimized.
Together they create a sustainable long-term strategy for employer GLP-1 management.
What This Means for Employers Moving Forward
If you’ve paused or delayed GLP-1 coverage due to cost, the landscape has changed. With market-aligned pricing, built-in clinical care, and continuous optimization through VerX, employers finally have a path to deliver GLP-1 therapy responsibly and sustainably.
This pricing update opens doors—not only for access, but for real, measurable outcomes:
- Reduced pharmacy spend
- Higher adherence
- Better weight-loss outcomes
- Increased employee well-being and productivity
- Predictable monthly costs for finance and HR teams
GLP-1s are transforming employee health. Now, for the first time, they can also fit the benefit budget.
Want the Full Breakdown?
Download our Price Update—A Corporate GLP-1 Program That Makes Financial Sense
For a deeper dive, book a 15 minute call with our team to see exactly how the new model works.
